In a patient with hidradenitis suppurativa who presents more than one week after onset of herpes zoster symptoms, what is the appropriate antiviral and overall management?

Management of Herpes Zoster After 1 Week in Patients with Hidradenitis Suppurativa

Antiviral therapy can still be beneficial even when initiated more than 1 week after herpes zoster symptom onset, particularly in patients with hidradenitis suppurativa who may be immunocompromised or on immunosuppressive therapy.

Antiviral Treatment Beyond 1 Week

While early treatment (within 72 hours) is optimal, late antiviral therapy remains indicated in specific circumstances 1, 2:

• Persistent or recalcitrant disease warrants treatment regardless of timing
• New lesion formation indicates ongoing viral replication and justifies antiviral initiation
• Immunocompromised status (common in HS patients on biologics or immunosuppressants) extends the treatment window

Recommended Antiviral Regimens

For immunocompetent patients with persistent disease 1, 2:

• Acyclovir 800 mg orally 5 times daily for 7 days, OR
• Valacyclovir 1000 mg orally every 8 hours for 7 days, OR
• Famciclovir 500 mg orally 3 times daily for 7 days

For immunocompromised patients (including those on HS biologics or immunosuppressants):

• More aggressive treatment is required 1, 2
• Consider prolonged therapy with dose adjustment based on clinical response
• Monitor for acyclovir-resistant strains if lesions persist despite treatment

Critical Considerations in HS Patients

Immunosuppression Status

HS patients frequently receive immunomodulatory therapies 3, 4, 5, 6, 7:

• TNF-α inhibitors (adalimumab)
• IL-17 inhibitors (secukinumab, bimekizumab)
• Systemic antibiotics (clindamycin/rifampicin, tetracyclines)
• JAK inhibitors and other immunosuppressants

These medications increase herpes zoster risk and severity, making antiviral treatment more critical even when delayed 3.

Treatment Algorithm

1. Assess immune status: Document all current HS medications, particularly biologics and immunosuppressants
2. Evaluate disease activity:
   • Are new vesicles still forming? → Treat with antivirals
   • Is there ophthalmic involvement? → Urgent treatment regardless of timing
   • Is there disseminated disease? → Consider hospitalization and IV therapy
3. Initiate appropriate antiviral regimen based on immune status (see doses above)
4. Continue HS therapy unless severe herpes zoster requires temporary modification
5. Monitor for complications: Postherpetic neuralgia, secondary bacterial infection, dissemination

Common Pitfalls to Avoid

• Do not withhold antivirals solely based on the 1-week timeframe in immunocompromised patients 1, 2
• Do not discontinue HS biologics reflexively—coordinate with dermatology to assess risk-benefit 3
• Do not use topical antivirals alone—they are ineffective for varicella-zoster virus 1, 2
• Do not add corticosteroids to treat herpes zoster inflammation, as they can worsen viral replication

Pain Management

Herpes zoster pain requires specific attention 8:

• Initiate analgesics appropriate to pain severity (acetaminophen, NSAIDs, or opioids for severe pain)
• Consider gabapentin or pregabalin early to prevent postherpetic neuralgia
• Topical lidocaine may provide symptomatic relief

Follow-Up

Schedule reassessment within 1 week to evaluate:

• Treatment response and lesion healing
• Development of postherpetic neuralgia
• Need for prolonged antiviral therapy
• Safety of continuing HS immunosuppressive therapy

The key principle: immunocompromised status (common in HS) extends the therapeutic window for antivirals beyond the traditional 72-hour limit 1, 2, 3.